An Enantioselective Synthesis of Cis Perhydroisoquinoline LY235959.

J Org Chem

Chemical Process Research and Development Division, Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285-4813.

Published: February 1998

A novel synthesis of NMDA receptor antagonist LY235959 (1) has been achieved in 13% overall yield and 17 steps from (R)-pantolactone (7). Highlights of the synthesis include (a) use of a chiral auxiliary controlled asymmetric Diels-Alder reaction to provide the desired absolute and relative stereochemistry at C-4a, C-6, and C-8a, (b) an efficient alkylation of hindered iodide 13 using a novel amide benzophenone imine, (c) oxidative ring opening of the [2.2.2] bicyclic system to simultaneously functionalize the molecule for intramolecular cyclization and phosphonate introduction, and (d) an increased understanding of how the C-3 stereochemistry may be controlled by thermodynamic equilibration. Synthesis of epimer 20 in high overall yield makes this synthetic route attractive for future development efforts.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jo9717649DOI Listing

Publication Analysis

Top Keywords

enantioselective synthesis
4
synthesis cis
4
cis perhydroisoquinoline
4
perhydroisoquinoline ly235959
4
ly235959 novel
4
novel synthesis
4
synthesis nmda
4
nmda receptor
4
receptor antagonist
4
antagonist ly235959
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!